QSAR 20211 is around the corner and after last year’s cancellation, we are excited to be in attendance. We are pleased to be contributors to this year’s program through participation in two platform sessions in addition to poster presentations.
If you are a frequent reader of this blog, you have read about our work on the development of in silico toxicology protocols, the nitrosamine SAR working group, and the fit-for-purpose evaluation of acute toxicity models for GHS classification. If you haven’t read our blog entries on these previous topics, then I would like to encourage you to have a look through past topics.
During this conference, we are taking a wide-ranging look at the successes and challenges of developing protocols for various toxicological endpoints such as skin sensitization, genetic toxicity, acute toxicity, carcinogenicity, and organ toxicity (Dr. Arianna Bassan’s poster takes a closer look at this). We discuss how knowledge of adverse outcome pathways, integrated approaches to testing and assessment (IATA) and defined approaches are useful in defining the rules and principles which are used to combine mechanistic information and toxicological effects. The extent to which this information is defined differs for various endpoints. However, we can identify areas where in silico prediction of a specific effect or mechanism (acute oral toxicity, for example) is supported by robust data sets and fit for purpose evaluations- Dr. Glenn Myatt’s poster will provide details on this.
Dr. Kevin Cross’ talk on “Predicting N-Nitrosamine Activity from Structure-Activity Relationships’ will address the question “Can we do better at predicting N-nitrosamine carcinogenicity potency?” He will present an overview on the features which have been observed to lead to a reduction or elimination of potency of dialkyl-N-nitrosamines and how these features could be used to assist in predicting N-nitrosamine potency.
We hope to chat with you there, or contact me at email@example.com for further information.